Dimensional Fund Advisors LP Sells 75,210 Shares of Novo Nordisk A/S $NVO

Dimensional Fund Advisors LP lowered its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,250,848 shares of the company's stock after selling 75,210 shares during the quarter. Dimensional Fund Advisors LP's holdings in Novo Nordisk A/S were worth $45,969,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $25,000. WealthCollab LLC increased its stake in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company's stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Jackson Grant Investment Advisers Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Finally, Maseco LLP bought a new position in Novo Nordisk A/S during the 4th quarter worth approximately $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 0.3%

Novo Nordisk A/S stock opened at $47.20 on Monday. The company has a 50 day moving average of $46.92 and a 200-day moving average of $45.40. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock has a market capitalization of $210.74 billion, a PE ratio of 11.08, a price-to-earnings-growth ratio of 4.30 and a beta of 0.76.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on NVO shares. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Citigroup reissued a "neutral" rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Finally, Zacks Research downgraded Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Five research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.